New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:08 EDTIDIXIdenix appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
Idenix Pharmaceuticals announced that it has appointed Jacques Dumas, Ph.D., as its executive vice president and Chief Scientific Officer. Dr. Dumas is trained as a medicinal chemist and brings over 20 years of experience in pharmaceutical discovery and development, supporting a variety of programs in infectious diseases and oncology. He is a co-inventor of two marketed drugs in the field of oncology, Nexavar and Stivarga. His appointment will be effective January 20, 2014.
News For IDIX From The Last 14 Days
Check below for free stories on IDIX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
17:07 EDTIDIXIdenix reports Q2 EPS (43c), consensus (21c)
Reports Q2 revenue ($26.1M). At June 30, Idenix's cash and cash equivalents totaled $177.6M. The company continues to expect that its current cash and cash equivalents will be sufficient to sustain its operations into at least the second half of 2015. This guidance assumes no milestone payments or license fees, no reimbursement for development programs and no financing or merger.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use